Document:

EX-4.3

 Exhibit 4.3 
 NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUBJECT TO SECTION 6 BELOW, NO SALE OR DISPOSITION MAY
BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR HOLDER, SATISFACTORY TO COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT OR
RECEIPT OF A NO-ACTION LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION. 
 WARRANT TO PURCHASE 8,000 SHARES OF SERIES B CONVERTIBLE
PREFERRED STOCK 
 June 27, 2008 
 THIS CERTIFIES THAT, for value received, GE Capital Equity Investments, Inc. (“Holder”) is entitled to subscribe for and purchase eight thousand (8,000) shares of fully paid and
nonassessable Series B Convertible Preferred Stock of BIND Biosciences, Inc., a DE corporation (the “Company”), at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter
set forth. As used herein, the term “Preferred Stock” shall mean Company’s presently authorized Series B Convertible Preferred Stock, $0.0001 par value per share, and any stock into which such Preferred Stock may hereafter be
converted or exchanged and the term “Warrant Shares” shall mean the shares of Preferred Stock which Holder may acquire pursuant to this Warrant and any other shares of stock into which such shares of Preferred Stock may hereafter be
converted or exchanged. 
 1. Warrant Price. The “Warrant Price” shall initially be two and 50/100 dollars ($2.50) per share,
subject to adjustment as provided in Section 7 below. 
 2. Conditions to Exercise. The purchase right represented by this Warrant
may be exercised at any time, or from time to time, in whole or in part during the term commencing on the date hereof and ending at 5:00 P.M. Pacific time on the tenth anniversary of the date of this Warrant (the “Expiration Date”).

 3. Method of Exercise or Conversion; Payment; Issuance of Shares; Issuance of New Warrant. 

(a) Cash Exercise. Subject to Section 2 hereof, the purchase right represented by this Warrant may be exercised by Holder
hereof, in whole or in part, by the surrender of the original of this Warrant (together with a duly executed Notice of Exercise in substantially the form attached hereto) at the principal office of Company (as set forth in Section 19 below) and
by payment to Company, by certified or bank check, or wire transfer of immediately available funds, of an amount equal to the then applicable Warrant Price per share multiplied by the number of Warrant Shares then being purchased. In the event of
any exercise of the rights represented by this Warrant, certificates for the shares of stock so purchased shall be in the name of, and delivered to, Holder hereof, or as such Holder may direct (subject to the terms of transfer contained herein and
upon payment by such Holder hereof of any applicable transfer taxes). Such delivery shall be made within 30 days after exercise of this Warrant and at Company’s expense and, unless this Warrant has been fully exercised or expired, a new Warrant
having terms and conditions substantially identical to this Warrant and representing the portion of the Warrant Shares, if any, with respect to which this Warrant shall not have been exercised, shall also be issued to Holder hereof within 30 days
after exercise of this Warrant. 

 (b) Conversion. In lieu of exercising this Warrant as specified in Section 3(a),
Holder may from time to time convert this Warrant, in whole or in part, into Warrant Shares by surrender of the original of this Warrant (together with a duly executed Notice of Exercise in substantially the form attached hereto) at the principal
office of Company, in which event Company shall issue to Holder the number of Warrant Shares computed using the following formula: 
  

					
	X =	 	 Y (A-B)
	 	
		 	A	 	

 Where: 
 X = the number of Warrant Shares to be issued to Holder. 
 Y = the number of
Warrant Shares purchasable under this Warrant (at the date of such calculation). 
 A = the Fair Market Value of one share of
Company’s Preferred Stock (at the date of such calculation). 
 B = Warrant Price (as adjusted to the date of such
calculation). 
 (c) Fair Market Value. For purposes of this Section 3, Fair Market Value of one share of
Company’s Preferred Stock shall mean: 
 (i) In the event of an exercise in connection with an Initial Public Offering, the
per share Fair Market Value for the Preferred Stock shall be the offering price at which the underwriters initially sell common stock of Company (“Common Stock”) to the public multiplied by the number of shares of Common Stock into which
each share of Preferred Stock is then convertible; or 
 (ii) The average of the closing bid and asked prices of Common Stock
quoted in the Over-The-Counter Market Summary, the last reported sale price quoted on the Nasdaq Stock Market or on any other exchange on which the Common Stock is listed, whichever is applicable, as published in the Western Edition of the Wall
Street Journal for the three (3) trading days prior to the date of determination of Fair Market Value, multiplied by the number of shares of Common Stock into which each share of Preferred Stock is then convertible; or 

(iii) In the event of an exercise in connection with a merger, acquisition or other consolidation in which Company is not the surviving
entity, the per share Fair Market Value for the Preferred Stock shall be the value to be received per share of Preferred Stock by all holders of the Preferred Stock in such transaction as determined by the Board of Directors; or 

(iv) In any other instance, the per share Fair Market Value for the Preferred Stock shall be as determined in the reasonable good faith
judgment of Company’s Board of Directors. 
 In the event of 3(c)(iii) or 3(c)(iv), above, Company’s Board of Directors
shall prepare a certificate, to be signed by an authorized officer of Company, setting forth in reasonable detail the basis for and method of determination of the per share Fair Market Value of the Preferred Stock. The Board of Directors will also
certify to Holder that this per share Fair Market Value will be applicable to all holders of Company’s Preferred Stock. Such certification must be made to Holder at least ten (10) business days prior to the proposed effective date of the
merger, consolidation, sale, or other triggering event as defined in 3(c)(iii) or 3(c)(iv). 
 (d) Automatic Exercise. To
the extent this Warrant is not previously exercised, it shall be deemed to have been automatically converted in accordance with Sections 3(b) and 3(c) hereof (even 

  
 2 

 
if not surrendered) as of immediately before its expiration, involuntary termination or cancellation if the then-Fair Market Value of a Warrant Share exceeds the then-Warrant Price, unless Holder
notifies Company in writing to the contrary prior to such automatic exercise. 
 (e) Treatment of Warrant Upon Acquisition
of Company. 
 (i) Certain Definitions. For the purpose of this Warrant, “Acquisition” means any sale,
license, or other disposition of all or substantially all of the assets of Company, or any reorganization, consolidation, or merger of Company, or sale of outstanding Company securities by holders thereof, where the holders of Company’s
securities before the transaction beneficially own less than a majority of the outstanding voting securities of the successor or surviving entity after the transaction. For purposes of this Section 3(e), “Affiliate” shall mean any
person or entity that owns or controls directly or indirectly ten percent (10%) or more of the voting capital stock of Company, any person or entity that controls or is controlled by or is under common control with such persons or entities, and
each of such person’s or entity’s officers, directors, joint venturers or partners, as applicable. 
 (ii) Cash
Acquisition. In the event of an Acquisition in which the sole consideration is cash, Holder may either (a) exercise its conversion or purchase right under this Warrant and such exercise will be deemed effective immediately prior to the
consummation of such Acquisition or (b) permit the Warrant to expire upon the consummation of such Acquisition. Company shall provide Holder with written notice of any proposed Acquisition together with such reasonable information as Holder may
request in connection with such contemplated Acquisition giving rise to such notice, which is to be delivered to Holder not less than ten (10) business days prior to the closing of the proposed Acquisition. 

(iii) Asset Sale. In the event of an Acquisition that is an arms length sale of all or substantially all of Company’s assets
(and only its assets) to a third party that is not an Affiliate of Company (a “True Asset Sale”), Holder may either (a) exercise its conversion or purchase right under this Warrant and such exercise will be deemed effective
immediately prior to the consummation of such Acquisition or (b) permit the Warrant to continue until the Expiration Date if Company continues as a going concern following the closing of any such True Asset Sale. Company shall provide Holder
with written notice of any proposed asset sale together with such reasonable information as Holder may request in connection with such asset sale giving rise to such notice, which is to be delivered to Holder not less than ten (10) business
days prior to the closing of the proposed asset sale. 
 (iv) Assumption of Warrant. Upon the closing of any Acquisition
other than those particularly described in subsections (ii) and (iii) above, the successor entity shall assume the obligations of this Warrant, and this Warrant shall be exercisable for the same securities, cash, and property as would be
payable for the Warrant Shares issuable upon exercise of the unexercised portion of this Warrant as if such Warrant Shares were outstanding on the record date for the Acquisition and subsequent closing. The Warrant Price and/or number of Warrant
Shares shall be adjusted accordingly. 
 4. Representations and Warranties of Holder and Company. 

(a) Representations and Warranties by Holder. Holder represents and warrants to Company with respect to this purchase as follows:

 (i) Evaluation. Holder has substantial experience in evaluating and investing in private placement transactions of
securities of companies similar to Company so that Holder is capable of evaluating the merits and risks of its investment in Company and has the capacity to protect its interests. 

  
 3 

 (ii) Resale. Except for transfers to an affiliate of Holder, Holder is acquiring this
Warrant and the Warrant Shares issuable upon exercise of this Warrant (collectively the “Securities”) for investment for its own account and not with a view to, or for resale in connection with, any distribution thereof. Holder understands
that the Securities have not been registered under the Securities Act of 1933, as amended (the “Act”) by reason of a specific exemption from the registration provisions of the Act which depends upon, among other things, the bona fide
nature of the investment intent as expressed herein. 
 (iii) Rule 144. Holder acknowledges that the Securities must be
held indefinitely unless subsequently registered under the Act or an exemption from such registration is available. Holder is aware of the provisions of Rule 144 promulgated under the Act. 

(iv) Accredited Investor. Holder is an “accredited investor” within the meaning of Regulation D promulgated under the
Act. 
 (v) Opportunity To Discuss. Holder has had an opportunity to discuss Company’s business, management and
financial affairs with its management and an opportunity to review Company’s facilities. Holder understands that such discussions, as well as the written information issued by Company, were intended to describe the aspects of Company’s
business and prospects which Company believes to be material but were not necessarily a thorough or exhaustive description. 

(b) Representations and Warranties by Company. Company hereby represents and warrants to Holder that the statements in the
following paragraphs of this Section 4(b) are true and correct (a) as of the date hereof and (b) except where any such representation and warranty relates specifically to an earlier date, as of the date of any exercise of this
Warrant. 
 (i) Corporate Organization and Authority. Company (a) is a corporation duly organized, validly existing,
and in good standing in its jurisdiction of incorporation, (b) has the corporate power and authority to own and operate its properties and to carry on its business as now conducted and as proposed to be conducted; and (c) is qualified as a
foreign corporation in all jurisdictions where such qualification is required, except where the failure to be so qualified could not reasonably be expected to have a material adverse effect. 

(ii) Corporate Power. Company has all requisite legal and corporate power and authority to execute, issue and deliver this Warrant,
to issue the Warrant Shares issuable upon exercise or conversion of this Warrant, and to carry out and perform its obligations under this Warrant and any related agreements. 
 (iii) Authorization; Enforceability. All corporate action on the part of Company, its officers, directors and shareholders necessary for the authorization, execution, delivery and performance of
its obligations under this Warrant and for the authorization, issuance and delivery of this Warrant and the Warrant Shares issuable upon exercise of this Warrant has been taken and this Warrant constitutes the legally binding and valid obligation of
Company enforceable in accordance with its terms. 
 (iv) Valid Issuance of Warrant and Warrant Shares. This Warrant has
been validly issued and is free of restrictions on transfer other than restrictions on transfer set forth herein and under applicable state and federal securities laws. The Warrant Shares issuable upon

  
 4 

 
conversion of this Warrant, when issued, sold and delivered in accordance with the terms of this Warrant for the consideration expressed herein, will be duly and validly issued, fully paid and
nonassessable, and will be free of restrictions on transfer other than restrictions on transfer under this Warrant and under applicable state and federal securities laws. Subject to applicable restrictions on transfer, the issuance and delivery of
this Warrant and the Warrant Shares issuable upon exercise or conversion of this Warrant are not subject to any preemptive or other similar rights or any liens or encumbrances except as specifically set forth in Company’s Certificate of
Incorporation or this Warrant. The offer, sale and issuance of the Warrant Shares, as contemplated by this Warrant, are exempt from the prospectus and registration requirements of applicable United States federal and state security laws, and neither
Company nor any authorized agent acting on its behalf has or will take any action hereafter that would cause the loss of such exemption. 
 (v) No Conflict. The execution, delivery, and performance of this Warrant will not result in (a) any violation of, be in conflict with, or constitute a default under, with or without the
passage of time or the giving of notice (1) any provision of Company’s Certificate of Incorporation or by-laws; (2) any provision of any judgment, decree, or order to which Company is a party, by which it is bound, or to which any of
its material assets are subject; (3) any contract, obligation, or commitment to which Company is a party or by which it is bound; or (4) any statute, rule, or governmental regulation applicable to Company, or (b) the creation of any
lien, charge or encumbrance upon any assets of Company. 
 (vi) Capitalization. The authorized capital stock of the
Company consists of 25,811,600 shares, consisting of 16,800,000 shares of common stock, $0.0001 par value per share, and 9,011,600 shares of preferred stock, $0.0001 par value per share of which 2,461,600 shares have been designated Series A
Convertible Preferred Stock and 6,550,000 shares have been designated Series B Convertible Preferred Stock. Schedule 1 sets forth all of the outstanding shares of common stock and preferred stock and outstanding options, warrants, convertible
securities, convertible debentures, and rights to acquire, subscribe for, and/or purchase any common stock, preferred stock and/or other capital stock of the Company or any securities or debentures convertible into or exchangeable for common stock,
preferred stock and/or other capital stock of the Company. Company has reserved 8,000 shares of Common Stock for issuance upon conversion of the Preferred Stock. 
 (vii) Warrant Price. The Warrant Price is no greater than the lowest price at which Company has issued Series B Convertible Preferred Stock to an unrelated third party in an arm’s length
transaction. 
 5. Legends. 
 (a) Legend. Each certificate representing the Warrant Shares shall be endorsed with substantially the following legend: 

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AND MAY NOT BE TRANSFERRED (UNLESS SUCH TRANSFER IS TO AN
AFFILIATE OF HOLDER) UNLESS COVERED BY AN EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT, A “NO ACTION” LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION WITH RESPECT TO SUCH TRANSFER, A TRANSFER MEETING THE REQUIREMENTS OF RULE 144 OF
THE SECURITIES AND EXCHANGE COMMISSION, OR (IF REASONABLY REQUIRED BY COMPANY) AN OPINION OF COUNSEL SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY SUCH TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 

  
 5 

 Company need not enter into its stock records a transfer of Warrant Shares unless the
conditions specified in the foregoing legend are satisfied. Company may also instruct its transfer agent not to allow the transfer of any of the Warrant Shares unless the conditions specified in the foregoing legend are satisfied. 

(b) Removal of Legend and Transfer Restrictions. The legend relating to the Act endorsed on a certificate pursuant to paragraph
5(a) of this Warrant shall be removed and Company shall issue a certificate without such legend to Holder if (i) the Securities are registered under the Act and a prospectus meeting the requirements of Section 10 of the Act is available or
(ii) Holder provides to Company an opinion of counsel for Holder reasonably satisfactory to Company, a no-action letter or interpretive opinion of the staff of the Securities and Exchange Commission (“SEC”) reasonably satisfactory to
Company, or other evidence reasonably satisfactory to Company, to the effect that public sale, transfer or assignment of the Securities may be made without registration and without compliance with any restriction such as Rule 144. 

6. Condition of Transfer or Exercise of Warrant. It shall be a condition to any transfer or exercise of this Warrant that at the time of such
transfer or exercise, Holder shall provide Company with a representation in writing that Holder or transferee is acquiring this Warrant and the shares of Preferred Stock to be issued upon exercise for investment purposes only and not with a view to
any sale or distribution, or will provide Company with a statement of pertinent facts covering any proposed distribution. As a further condition to any transfer of this Warrant or any or all of the shares of Preferred Stock issuable upon exercise of
this Warrant, other than a transfer registered under the Act, Company may request a legal opinion, in form and substance satisfactory to Company and its counsel, reciting the pertinent circumstances surrounding the proposed transfer and stating that
such transfer is exempt from the registration and prospectus delivery requirements of the Act. Company shall not require Holder to provide an opinion of counsel if the transfer is to an affiliate of Holder. As further condition to each transfer, at
the request of Company, Holder shall surrender this Warrant to Company and the transferee shall receive and accept a Warrant, of like tenor and date, executed by Company. 
 7. Adjustment for Certain Events. The number and kind of securities purchasable upon the exercise of this Warrant and the Warrant Price shall be subject to adjustment from time to time upon the
occurrence of certain events, as follows: 
 (a) Reclassification or Merger. In case of (i) any reclassification or
change of securities of the class issuable upon exercise of this Warrant (other than a change in par value, or from par value to no par value, or from no par value to par value, or as a result of a subdivision or combination), (ii) any merger
of Company with or into another corporation (other than a merger with another corporation in which Company is the acquiring and the surviving corporation and which does not result in any reclassification or change of outstanding securities issuable
upon exercise of this Warrant), or (iii) any sale of all or substantially all of the assets of Company, Company, or such successor or purchasing corporation, as the case may be, shall duly execute and deliver to Holder a new Warrant (in form and
substance satisfactory to Holder of this Warrant), or Company shall make appropriate provision without the issuance of a new Warrant, so that Holder shall have the right to receive, at a total purchase price not to exceed that payable upon the
exercise of the unexercised portion of this Warrant, and in lieu of the Warrant Shares theretofore issuable upon exercise or conversion of this Warrant, the kind and amount of shares of stock, other securities, money and property receivable upon
such reclassification, change, merger or sale by a holder of the number of shares of Preferred Stock then purchasable under this Warrant, or in the case of such a merger or sale in which the consideration paid consists all or in part of assets other
than securities of the successor or purchasing corporation, at the option of Holder, the securities of the successor or purchasing corporation having a value at the time of the transaction equivalent to the value of the Warrant Shares purchasable
upon exercise of this Warrant at the time of the transaction. Any new Warrant shall provide for 

  
 6 

 
adjustments that shall be as nearly equivalent as may be practicable to the adjustments provided for in this Section 7. The provisions of this subparagraph (a) shall similarly apply to
successive reclassifications, changes, mergers and transfers. 
 (b) Subdivision or Combination of Shares. If Company at
any time while this Warrant remains outstanding and unexpired shall subdivide or combine its outstanding shares of Preferred Stock, the Warrant Price shall be proportionately decreased and the number of Warrant Shares issuable hereunder shall be
proportionately increased in the case of a subdivision and the Warrant Price shall be proportionately increased and the number of Warrant Shares issuable hereunder shall be proportionately decreased in the case of a combination. 

(c) Stock Dividends and Other Distributions. If Company at any time while this Warrant is outstanding and unexpired shall
(i) pay a dividend with respect to Preferred Stock payable in Preferred Stock, then the Warrant Price shall be adjusted, from and after the date of determination of shareholders entitled to receive such dividend or distribution, to that price
determined by multiplying the Warrant Price in effect immediately prior to such date of determination by a fraction (A) the numerator of which shall be the total number of shares of Preferred Stock outstanding immediately prior to such dividend
or distribution, and (B) the denominator of which shall be the total number of shares of Preferred Stock outstanding immediately after such dividend or distribution; or (ii) make any other distribution with respect to Preferred Stock
(except any distribution specifically provided for in Sections 7(a) and 7(b)), then, in each such case, provision shall be made by Company such that Holder shall receive upon exercise of this Warrant a proportionate share of any such dividend or
distribution as though it were Holder of the Warrant Shares as of the record date fixed for the determination of the shareholders of Company entitled to receive such dividend or distribution. 

(d) Adjustment of Number of Shares. Upon each adjustment in the Warrant Price, the number of Warrant Shares purchasable hereunder
shall be adjusted, to the nearest whole share, to the product obtained by multiplying the number of Warrant Shares purchasable immediately prior to such adjustment in the Warrant Price by a fraction, the numerator of which shall be the Warrant Price
immediately prior to such adjustment and the denominator of which shall be the Warrant Price immediately thereafter. 
 (e)
Adjustment for Dilutive Issuance. The Warrant Price and the number of Warrant Shares issuable upon exercise of this Warrant or, if the Warrant Shares are Preferred Stock, the number of shares of Common Stock issuable upon conversion of the
Warrant Shares, shall be subject to adjustment, from time to time In the manner set forth in Company’s Certificate of Incorporation as if the Warrant Shares were issued and outstanding on and as of the date of any such required adjustment. The
provisions set forth for the Warrant Shares in Company’s Certificate of Incorporation relating to the above in effect as of the date hereof may not be amended, modified or waived, without the prior written consent of Holder unless such
amendment, modification or waiver affects the rights associated with the Warrant Shares in the same manner as such amendment, modification or waiver affects the rights associated with all other shares of the same series and class as the Warrant
Shares. 
 (f) Adjustment for Pay-to-Play Transaction. In the event that Company’s Certificate of Incorporation
provides, or is amended to so provide, for the amendment or modification of the rights, preferences or privileges of the Preferred Stock, or the reclassification, conversion or exchange of the Preferred Stock, in the event that a holder thereof
fails to participate in an equity financing transaction (a “Pay-to-Play Provision”), and in the event that such Pay-to-Play Provision becomes operative, this Warrant shall automatically and without any action required become exercisable
for that number and type of shares of equity securities as would have been issued or exchanged, or would have remained outstanding, in respect of the Warrant Shares issuable hereunder had this Warrant been exercised in full prior to such event, and
had Holder participated in the equity financing to the maximum extent permitted. 

  
 7 

 8. Notice of Adjustments. Whenever any Warrant Price or the kind or number of securities issuable
under this Warrant shall be adjusted pursuant to Section 7 hereof, Company shall prepare a certificate signed by an officer of Company setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the
method by which such adjustment was calculated, and the Warrant Price and number or kind of shares issuable upon exercise of this Warrant after giving effect to such adjustment, and shall cause copies of such certificate to be mailed (by certified
or registered mail, return receipt required, postage prepaid) within thirty (30) days of such adjustment to Holder as set forth in Section 19 hereof. 
 9. Financial and Other Reports. From time to time up to the earlier of the Expiration Date or the complete exercise of this Warrant, Company shall furnish to Holder, if Company is a private
company, (a) unaudited consolidated and, if available, consolidating balance sheets, statements of operations and cash flow statements within 45 days of each month end, in a form acceptable to Holder and certified by Company’s president or
chief financial officer, and (b) Company’s complete annual audited consolidated and, if available, consolidating balance sheets, statements of operations and cash flow statements certified by an independent certified public accountant
selected by Company and satisfactory to Holder within 180 days of the fiscal year end or, if sooner, at such time as Company’s Board of Directors receives the audit. If Company is a publicly held company, it shall deliver to Holder quarterly
unaudited consolidated and, if available, consolidating balance sheets, statements of operations and cash flow statements and annual audited consolidated and, if available, consolidating balance sheets, statements of operations and cash flow
statements, certified by a recognized firm of certified public accountants, within 5 days after the statements are required to be provided to the SEC, and if Holder requests, Company shall deliver to Holder monthly unaudited consolidated balance
sheets, statements of operations and cash flow statements within 30 days after the end of each month. All such statements are to be prepared using GAAP and, if Company is a publicly held company, are to be in compliance with SEC requirements. At the
time of Company’s delivery of quarterly financial statements in accordance with this Section 9, Company shall also deliver to Holder an updated capitalization information of Company. 

10. Transferability of Warrant. This Warrant is transferable on the books of Company at its principal office by the registered Holder hereof upon
surrender of this Warrant properly endorsed, subject to compliance with Section 6 and applicable federal and state securities laws. Company shall issue and deliver to the transferee a new Warrant representing the Warrant so transferred. Upon
any partial transfer, Company will issue and deliver to Holder a new Warrant with respect to the Warrant not so transferred. Holder shall not have any right to transfer any portion of this Warrant to any direct competitor of Company. 

11. Registration Rights. Company grants registration rights to Holder of this Warrant for any Common Stock of Company obtained by Holder upon
exercise or conversion of this Warrant, or subsequent conversion of the Preferred Stock, in parity to the registration rights granted to other holders of the Preferred Stock and agrees that Holder shall be added as a party to that certain First
Amended and Restated Investors’ Rights Agreement dated as of November 9, 2007 of Company (the “Registration Rights Agreement”), and that the Warrant Shares shall be “Registrable Securities” under the Registration Rights
Agreement. 
 12. No Fractional Shares. No fractional share of Preferred Stock will be issued in connection with any exercise or
conversion hereunder, but in lieu of such fractional share Company shall make a cash payment therefor upon the basis of the Warrant Price then in effect. 
 13. Charges, Taxes and Expenses. Issuance of certificates for shares of Preferred Stock upon the exercise or conversion of this Warrant shall be made without charge to Holder for any United States
or state of the United States documentary stamp tax or other incidental expense with respect to the issuance of such certificate, all of which taxes and expenses shall be paid by Company, and such certificates shall be issued in the name of Holder.

  
 8 

 14. No Shareholder Rights Until Exercise. Except as expressly provided herein, this Warrant does not
entitle Holder to any voting rights or other rights as a shareholder of Company prior to the exercise hereof. 
 15. Registry of Warrant.
Company shall maintain a registry showing the name and address of the registered Holder of this Warrant. This Warrant may be surrendered for exchange or exercise, in accordance with its terms, at such office or agency of Company, and Company and
Holder shall be entitled to rely in all respects, prior to written notice to the contrary, upon such registry. 
 16. Loss, Theft,
Destruction or Mutilation of Warrant. Upon receipt by Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant, and, in the case of loss, theft, or destruction, of indemnity reasonably
satisfactory to it, and, if mutilated, upon surrender and cancellation of this Warrant, Company will execute and deliver a new Warrant, having terms and conditions substantially identical to this Warrant, in lieu hereof. 

17. Miscellaneous. 
 (a)
Issue Date. The provisions of this Warrant shall be construed and shall be given effect in all respect as if it had been issued and delivered by Company on the date hereof. 

(b) Successors. This Warrant shall be binding upon any successors or assigns of Company. 

(c) Headings. The headings used in this Warrant are used for convenience only and are not to be considered in construing or
interpreting this Warrant. 
 (d) Saturdays, Sundays, Holidays. If the last or appointed day for the taking of any action
or the expiration of any right required or granted herein shall be a Saturday or a Sunday or shall be a legal holiday in the State of New York, then such action may be taken or such right may be exercised on the next succeeding day not a legal
holiday. 
 (e) Attorney’s Fees. In the event of any dispute between the parties concerning the terms and provisions
of this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorney’s fees. 
 18. No Impairment. Company will not, by amendment of its Certificate of Incorporation or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of Holder hereof against impairment. Without limiting
the breadth of the foregoing, Company will not cause the Series B Convertible Preferred Stock into which this Warrant is exercisable or convertible to be converted into Common Stock unless such conversion is effected as part of the conversion of all
Company’s outstanding series of preferred stock and other senior securities into Common Stock. 
 19. Addresses. Any notice required
or permitted hereunder shall be in writing and shall be mailed by overnight courier, registered or certified mail, return receipt requested, and postage prepaid, or otherwise delivered by hand or by messenger, addressed as set forth below, or at
such other address as Company or Holder hereof shall have furnished to the other party in accordance with the delivery instructions set forth in this Section 19. 

  
 9 

			
	If to Company:	  	 BIND Biosciences, Inc.
 101
Binney Street
 Cambridge, MA 02142

Attn: Glenn Batchelder

		
	If to Holder:	  	 GE Capital Equity Investments, Inc.
 201 Merritt 7, 1st Floor
 P.O. Box 5201
 Norwalk, Connecticut 06851
 Attn: General Counsel

		
	With copies to:	  	 General Electric Capital Corporation
 c/o GE Healthcare Financial Services, Inc.
 83 Wooster Heights Road, Fifth Floor

Danbury, Connecticut 06810
 Attn: Senior Managing
Director and
          Senior Vice President of Risk

 If mailed by registered or certified mail, return receipt requested, and postage prepaid, notice shall be
deemed to be given five (5) days after being sent, and if sent by overnight courier, by hand or by messenger, notice shall be deemed to be given when delivered (if on a business day, and if not, on the next business day). 

20. WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A
TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS WARRANT OR THE WARRANT SHARES. 
 21. GOVERNING LAW. THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. 
 [Remainder of page intentionally left blank] 

  
 10 

 IN WITNESS WHEREOF, Company has caused this Warrant to be executed by its officer thereunto
duly authorized. 
  

			
	BIND Biosciences, Inc.
		
	By:	 	/s/ Andrea K. Franz
	Name:	 	 Andrea K. Franz

	Title:	 	 CFO

 Dated as of June 27, 2008. 

 NOTICE OF EXERCISE 

 

			
	To:	  	
	[Name of Company]	  	
	  
	  	
	  
	  	
	  
	  	

  

	1.	The undersigned Warrantholder (“Holder”) elects to acquire shares of the Series      Convertible Preferred Stock (the “Preferred
Stock”) of                      (the “Company”), pursuant to the terms of the Stock Purchase Warrant dated
                 , 200     (the “Warrant”). 

  

	2.	Holder exercises its rights under the Warrant as set forth below: 

  

			
	(        )	 	Holder elects to purchase              shares of Preferred Stock as provided in Section 3(a) and tenders herewith a check
in the amount of $         as payment of the purchase price.
		
	(        )	 	Holder elects to convert the purchase rights into shares of Preferred Stock as provided in Section 3(b) of the Warrant.

  

	3.	Holder surrenders the Warrant with this Notice of Exercise. 

 Holder represents that it is acquiring the aforesaid shares of Preferred Stock for investment and not with a view to or for resale in connection with distribution and that Holder has no present intention
of distributing or reselling the shares. 
 Please issue a certificate representing the shares of the Preferred Stock in the name of Holder or
in such other name as is specified below: 
  

									
		 	Name:	 	  
	 		 	
					
		 	Address:	 	  
	 		 	
					
		 	Taxpayer I.D.:	 	  
	 		 	

  

					
	[NAME OF HOLDER]
		
	By:	 	  

		 	Name:	 	  

		 	Title:	 	  

		
	Date:	 	                 , 200  

 ANNEX A 
 Company Capitalization Information 
 Outstanding Capital Stock: 

Common Stock:        4,257,582 

Series A Convertible Preferred Stock:        2,461,600 

Series B Convertible Preferred Stock:        6,450,000 

Outstanding options, warrants, convertible securities, convertible debentures, and rights to acquire, subscribe for, and/or purchase any common stock,
preferred stock and/or other capital stock of the Company or any securities or debentures convertible into or exchangeable for common stock, preferred stock and/or other capital stock of the Company: 

Options for common stock:    [706,003]EX-4.4

 Exhibit 4.4 
 NEITHER THIS WARRANT NOR THE SHARES OF CAPITAL STOCK ISSUABLE UPON ITS EXERCISE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD,
OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. THIS WARRANT MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF THIS WARRANT. 
 WARRANT AGREEMENT 
 To Purchase Shares of Preferred Stock of 

BIND Biosciences, Inc. 
 Dated as of January 10, 2011 (the “Effective Date”) 

WHEREAS, BIND Biosciences, Inc., a Delaware corporation (the “Company”), has entered into a Loan and Security Agreement
of even date herewith (the “Loan Agreement”) with Hercules Technology III, L.P., a Delaware limited partnership (the “Warrantholder”); 
 WHEREAS, the Company desires to grant to Warrantholder, in consideration for, among other things, the financial accommodations provided for in the Loan Agreement, the right to purchase shares of Preferred
Stock (as defined below) pursuant to this Warrant Agreement (the “Agreement”); 
 NOW, THEREFORE, in
consideration of the Warrantholder executing and delivering the Loan Agreement and providing the financial accommodations contemplated therein, and in consideration of the mutual covenants and agreements contained herein, the Company and
Warrantholder agree as follows: 
  

	 	SECTION 1.	GRANT OF THE RIGHT TO PURCHASE PREFERRED STOCK. 

 For value received, the Company hereby grants to the Warrantholder, and the Warrantholder is entitled, upon the terms and subject to the conditions hereinafter set forth, to subscribe for and purchase,
from the Company, up to the aggregate number of shares of fully paid and non-assessable shares of the Preferred Stock (as defined below) as is equal to the quotient derived by dividing (a) $600,000 by (b) the Exercise Price (as defined
below), at a purchase price per share equal to the Exercise Price. The aggregate number of shares of Preferred Stock that the Warrantholder may initially subscribe for and purchase under this Agreement shall equal the quotient derived by dividing
(a) $100,200 by (b) the Exercise Price. If the Company elects to have the Availability Period (as defined in and pursuant to the Loan Agreement) extend through June 30, 2011, then the aggregate number of shares of Preferred Stock that
the Warantholder may subscribe for and purchase under this Agreement shall be increased by an amount equal to the quotient derived by dividing (a) $100,200 by (b) the Exercise Price. If the aggregate Advances (as defined in the Loan
Agreement) exceed $2,000,000 at any time, then the aggregate number of shares of Preferred Stock that the Warantholder may subscribe for and purchase under this Agreement shall be increased by an amount equal to the quotient derived by dividing
(a) $399,600 by (b) the Exercise Price. The number of shares and Exercise Price are subject to adjustment as provided in Section 8. As used herein, the following terms shall have the following meanings: 

“Act” means the Securities Act of 1933, as amended. 

 “Charter” means the Company’s Certificate of Incorporation or other
constitutional document, as may be amended and/or restated from time to time. 
 “Common Stock” means the
Company’s common stock, $0.0001 par value per share; 
 “Exercise Price” means a price equal to the lower
of (a) $4.00 per share if this Agreement is exercised for Series C-1 Preferred Stock (as defined below) or (b) the price per share paid in the Equity Financing (as defined below) if this Agreement is exercised for securities sold in the
Equity Financing, in each case, subject to adjustment from time to time as provided in this Agreement; 
 “Initial Public
Offering” means the initial underwritten public offering of Common Stock pursuant to a registration statement under the Act, which registration statement for the public offering has been declared effective by the Securities and Exchange
Commission (“SEC”); 
 “Merger Event” means a merger or consolidation involving the Company in
which the Company is not the surviving entity or in which the outstanding shares of the Company’s capital stock are otherwise converted into or exchanged for shares of capital stock of another entity. 

“Preferred Stock” means the Series C-1 Preferred Stock, $0.0001 par value per share, of the Company (the “Series
C-1 Preferred Stock”) and any other stock into or for which the Series C-1 Preferred Stock may be converted or exchanged; provided, that if Warrantholder exercises its right under Section 8(g) of this Agreement to have the class and
series of equity securities issued in the Equity Financing (as defined below) issuable upon exercise of this Warrant, then the Preferred Stock shall be of the class and type sold in such financing and any other stock into or for which such Preferred
Stock may be converted or exchanged. Upon and after the occurrence of an event which results in the automatic or voluntary conversion, redemption or retirement of all (but not less than all) of the outstanding shares of such Preferred Stock,
including, without limitation, the consummation of an Initial Public Offering of the Common Stock in which such a conversion occurs, then from and after the date upon which such outstanding shares are so converted, redeemed or retired, (i) this
Warrant shall be exercisable for such number of shares of Common Stock as is equal to the number of shares of Common Stock that each share of Preferred Stock was converted into, multiplied by the number of shares of Preferred Stock subject to this
Warrant immediately prior to such conversion, (ii) the Purchase Price shall be the Purchase Price in effect immediately prior to such conversion divided by the number of shares of Common Stock into which each share of Preferred Stock was
converted, and (iii) all references to this Warrant to “Preferred Stock” shall thereafter be deemed to refer to “Common Stock.” Notwithstanding the foregoing, in no event shall “Preferred Stock” include any debt
security or other evidences of indebtedness of the Company. 
 “Purchase Price” means, with respect to any
exercise of this Agreement, an amount equal to the Exercise Price as of the relevant time multiplied by the number of shares of Preferred Stock requested to be exercised under this Agreement pursuant to such exercise. 

“Rights Agreement” means that certain Third Amended and Restated Investors’ Rights Agreement, between the Company
and certain of its stockholders, dated June 14, 2010, as may be amended and/or restated from time to time. 

  
 2 

	 	SECTION 2.	TERM OF THE AGREEMENT. 

 Except
as otherwise provided for herein, the term of this Agreement and the right to purchase Preferred Stock as granted herein (the “Warrant”) shall commence on the Effective Date and shall be exercisable for a period ending upon the later to
occur of (i) ten (10) years from the Effective Date; and (ii) five (5) years following the effective date of the registration statement for the Initial Public Offering, if any, that occurs before the tenth anniversary of the
Effective Date (the later of (i) and (ii), the “Expiration Date”). 
  

	 	SECTION 3.	EXERCISE OF THE PURCHASE RIGHTS. 

(a) Exercise. The purchase rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part, at any
time, or from time to time, prior to the Expiration Date, by tendering to the Company at its principal office a notice of exercise in the form attached hereto as Exhibit I (the “Notice of Exercise”), duly completed and
executed. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance with the terms set forth below, and in no event later than five (5) business days thereafter, the Company shall issue to the
Warrantholder a certificate for the number of shares of Preferred Stock purchased and shall execute the acknowledgment of exercise in the form attached hereto as Exhibit II (the “Acknowledgment of Exercise”) indicating the
number of shares which remain subject to future exercises, if any. 
 The Purchase Price may be paid at the Warrantholder’s
election either (i) by cash or check, or (ii) by surrender of all or a portion of the Warrant for shares of Preferred Stock to be exercised under this Agreement and, if applicable, an amended Agreement representing the remaining number of
shares purchasable hereunder, as determined below (“Net Issuance”). If the Warrantholder elects the Net Issuance method of exercise, the Company will issue Preferred Stock in accordance with the following formula: 

 

					
		  		  	 X = Y(A-B)

            A

			
	Where:	  	X =	  	the number of shares of Preferred Stock to be issued to the Warrantholder.
			
		  	Y =	  	the number of shares of Preferred Stock requested to be exercised under this Agreement.
			
		  	A =	  	the fair market value of one (1) share of Preferred Stock at the time of issuance of such shares of Preferred Stock.
			
		  	B =	  	the Exercise Price.

 For purposes of the above calculation, current fair market value of Preferred Stock shall mean with
respect to each share of Preferred Stock: 
 (i) if the exercise is in connection with an Initial Public
Offering, and if the Company’s Registration Statement relating to such Initial Public Offering has been declared effective by the SEC, then the fair market value per share shall be the product of (x) the initial “Price to Public”
of the Common Stock specified in the final prospectus with respect to the offering and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise; 

  
 3 

 (ii) if the exercise is after, and not in connection with, an Initial Public
Offering, then: 
 (A) if the Common Stock is traded on a securities exchange, then the fair market value shall
be deemed to be the product of (x) the average of the closing prices over a five (5) day period ending three (3) days before the day the current fair market value of the securities is being determined and (y) the number of shares
of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise; or 
 (B)
if the Common Stock is traded over-the-counter, then the fair market value shall be deemed to be the product of (x) the average of the closing bid and asked prices quoted on the NASDAQ system (or similar system) over the five (5) day
period ending three (3) days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such
exercise; 
 (iii) if at any time the Common Stock is not listed on any securities exchange or quoted in the
NASDAQ National Market or the over-the-counter market, the current fair market value of Preferred Stock shall be the product of (x) the fair market value of Common Stock as determined in good faith by its Board of Directors and (y) the
number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise, provided that in the event that the exercise is in connection with a Merger Event, the fair market value of Preferred Stock shall
be deemed to be the per share value received by the holders of the Preferred Stock on an as-converted-to common stock basis pursuant to such Merger Event. 
 Upon partial exercise by either cash or Net Issuance, the Company shall promptly issue an amended Agreement representing the remaining number of shares of Preferred Stock purchasable hereunder. All other
terms and conditions of such amended Agreement shall be identical to those contained herein, including, but not limited to the Effective Date hereof. 
 (b) Exercise Prior to Expiration. To the extent this Agreement is not previously exercised as to all Preferred Stock subject hereto, and if the fair market value of one share of the Preferred Stock
is greater than the Exercise Price then in effect, this Agreement shall be deemed automatically exercised pursuant to Section 3(a) (even if not surrendered) immediately prior to the Expiration Date. For purposes of such automatic exercise, the
fair market value of one share of the Preferred Stock upon such Expiration Date shall be determined pursuant to Section 3(a). To the extent this Agreement or any portion thereof is deemed automatically exercised pursuant to this
Section 3(b), the Company agrees to promptly notify the Warrantholder of the number of shares of Preferred Stock, if any, the Warrantholder is to receive by reason of such automatic exercise. 

 

	 	SECTION 4.	RESERVATION OF SHARES. 

 During
the term of this Agreement, the Company will at all times have authorized and reserved a sufficient number of shares of its Series C-1 Preferred Stock to provide for the exercise of the rights to purchase Series C-1 Preferred Stock as provided for
herein, and shall have authorized and reserved a sufficient number of shares of Common Stock to provide for the conversion of the Series C-1 Preferred Stock available hereunder. 

  
 4 

	 	SECTION 5.	NO FRACTIONAL SHARES OR SCRIP. 

No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Agreement, but in lieu of such
fractional shares, the Company shall make a cash payment therefor in an amount equal to the product of (i) the Exercise Price then in effect multiplied by (ii) the fraction of a share. 

 

	 	SECTION 6.	REGISTRATION RIGHTS; NO OTHER RIGHTS AS STOCKHOLDER. 

 The Rights Agreement has been amended to provide that the Common Stock into which the Preferred Stock is convertible shall be “Registrable Securities”, and Warrantholder shall have the rights
of, and be subject to the obligations of, a “Holder” under the Section 3 of the Rights Agreement. This Agreement does not entitle the Warrantholder to any voting rights or other rights as a stockholder of the Company prior to the
exercise of this Agreement. 
  

	 	SECTION 7.	WARRANTHOLDER REGISTRY. 

 The
Company shall maintain a registry showing the name and address of the registered holder of this Agreement. The Warrantholder’s initial address, for purposes of such registry, is set forth in Section 12(e) of this Agreement. The
Warrantholder may change such address by giving written notice of such changed address to the Company. 
  

	 	SECTION 8.	ADJUSTMENT RIGHTS. 

 The Exercise
Price and the number of shares of Preferred Stock purchasable hereunder are subject to adjustment, as follows: 
 (a) Merger
Event. If at any time there shall be Merger Event, then, as a part of such Merger Event, lawful provision shall be made so that the Warrantholder shall thereafter be entitled to receive, upon exercise of this Agreement, the number of shares of
capital stock or other securities or cash or other property resulting from such Merger Event that would have been issuable if Warrantholder had exercised this Agreement immediately prior to the Merger Event. In any such case, appropriate adjustment
(as determined in good faith by the Company’s Board of Directors) shall be made in the application of the provisions of this Agreement with respect to the rights and interests of the Warrantholder after the Merger Event to the end that the
provisions of this Agreement (including adjustments of the Exercise Price and number of shares of Preferred Stock purchasable) shall be applicable in their entirety and to the greatest extent possible. Without limiting the foregoing, in connection
with any Merger Event, upon the closing thereof, the successor or surviving entity shall assume the obligations of this Agreement. In connection with a Merger Event and upon Warrantholder’s written election to the Company at least ten
(10) days prior to the effectiveness of such Merger Event, the Company shall cause this Warrant Agreement to be exchanged for the consideration that Warrantholder would have received if Warrantholder chose to exercise its right to have shares
issued pursuant to the Net Issuance provisions of this Warrant Agreement, without actually exercising such right, acquiring such shares, and exchanging such shares for such consideration. 

(b) Reclassification of Shares. Except as set forth in Section 8(a), if the Company at any time shall, by combination,
reclassification, exchange or subdivision of securities or otherwise, change any of the securities as to which purchase rights under this Agreement exist into the same or a different number of securities of the same class or any other class or
classes, this Agreement shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under this
Agreement immediately prior to such combination, reclassification, exchange, subdivision or other change. 

  
 5 

 (c) Subdivision or Combination of Shares. If the Company at any time shall subdivide
or combine its Preferred Stock, (i) in the case of a subdivision, the Exercise Price shall be proportionately decreased, and the number of shares of Preferred Stock issuable upon exercise of this Agreement shall be proportionately increased, or
(ii) in the case of a combination, the Exercise Price shall be proportionately increased, and the number of shares of Preferred Stock issuable upon the exercise of this Agreement shall be proportionately decreased. 

(d) Stock Dividends. If the Company at any time while this Agreement is outstanding and unexpired shall: 

(i) pay a dividend with respect to the Preferred Stock payable in Preferred Stock, then the Exercise Price shall be
adjusted, from and after the date of determination of stockholders entitled to receive such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such date of determination by a fraction
(A) the numerator of which shall be the total number of shares of Preferred Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares of Preferred Stock
outstanding immediately after such dividend or distribution; or 
 (ii) make any other distribution with respect
to Preferred Stock (or stock into which the Preferred Stock is convertible), except any distribution specifically provided for in any other clause of this Section 8, then, in each such case, provision shall be made by the Company such that the
Warrantholder shall receive upon exercise or conversion of this Warrant a proportionate share of any such distribution as though it were the holder of the Preferred Stock (or other stock for which the Preferred Stock is convertible) as of the record
date fixed for the determination of the stockholders of the Company entitled to receive such distribution. 
 (e)
Antidilution Rights. Additional antidilution rights applicable to the Preferred Stock purchasable hereunder are as set forth in the Charter and shall be applicable with respect to the Preferred Stock issuable hereunder. The Company shall
promptly provide the Warrantholder with any restatement, amendment, modification or waiver of the Charter; provided, that no such amendment, modification or waiver shall impair or reduce the antidilution rights applicable to the Preferred
Stock as of the date hereof unless such amendment, modification or waiver applies to all then outstanding shares of Preferred Stock. For the avoidance of doubt, there shall be no duplicate anti-dilution adjustment pursuant to this subsection (e),
the forgoing subsection (d) and the Charter. 
 (f) Notice of Adjustments. If: (i) the Company shall declare
any dividend or distribution upon its stock, whether in stock, cash, property or other securities; (ii) the Company shall offer for subscription pro rata to the holders of any class of its Preferred Stock or other convertible stock any
additional shares of stock of any class or other rights; (iii) there shall be any Merger Event; (iv) there shall be an Initial Public Offering; (v) the Company shall sell, lease, exclusive license or otherwise transfer all or
substantially all of its assets; or (vi) there shall be any voluntary dissolution, liquidation or winding up of the Company; then, in connection with each such event, the Company shall send to the Warrantholder: (A) at least ten
(10) days’ prior written notice of the date on which the books of the Company shall close or a record shall be taken for such dividend, distribution, subscription rights (specifying the date on which the holders of Preferred Stock shall be
entitled thereto) or for determining rights to vote in respect of such Merger Event, dissolution, liquidation or winding up; (B) in the case of any such Merger Event, sale, lease, exclusive license or other transfer of all or substantially all
assets, dissolution, liquidation or winding up, at least ten (10) days’ prior written notice of the date when the same shall take place (and specifying the date on which the holders of Preferred Stock shall be entitled

  
 6 

 
to exchange their Preferred Stock for securities or other property deliverable upon such Merger Event, dissolution, liquidation or winding up); and (C) in the case of an Initial Public
Offering, the Company shall give the Warrantholder at least five (5) days’ written notice prior to the effective date of the registration statement therefor. 
 Each such written notice shall set forth, in reasonable detail, (i) the event requiring the notice, and (ii) if any adjustment is required to be made, (A) the amount of such adjustment,
(B) the method by which such adjustment was calculated, (C) the adjusted Exercise Price (if the Exercise Price has been adjusted), and (D) the number of shares subject to purchase hereunder after giving effect to such adjustment. Such
written notice shall be given by first class mail, postage prepaid, by reputable overnight courier with all charges prepaid or via electronic transmission, addressed to the Warrantholder at the address for Warrantholder set forth in
Section 12(g). 
 (g) Election. If (i) none of the purchase rights set forth in this Agreement have been
previously exercised and (ii) the Initial Public Offering has not been consummated, then at least ten (10) days prior to the consummation of the first private institutional equity financing of the Company generating cash proceeds of at
least $5,000,000 after the date hereof (an “Equity Financing”), the Company shall give written notice to the Warrantholder of such Equity Financing (the “Financing Notice”) setting forth a summary of the material
terms of such Equity Financing. For the avoidance of doubt, the issuance of securities in connection with a research, collaboration, technology license, development, marketing or other similar agreement or strategic partnership shall not be an
Equity Financing. Within three (3) business days following the date of such Financing Notice, the Warrantholder shall deliver written notice to the Company electing to have the class and series of equity securities issued in such Equity
Financing (instead of Series C-1 Preferred Stock) be the securities issuable upon exercise of this Warrant. If Warrantholder fails to exercise such right in a timely manner, the rights of Warrantholder under this Section 8(g) shall terminate
immediately and the Company shall have no further obligation under this Section 8(g). 
  

	 	SECTION 9.	REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. 

 The Company makes the following representations and warranties to Warrantholder as of the Effective Date. 
 (a) Reservation of Preferred Stock. The Series C-1 Preferred Stock issuable upon exercise of the Warrantholder’s rights under this Agreement has been duly and validly reserved and, when the
Preferred Stock is issued in accordance with the provisions of this Agreement, will be validly issued, fully paid and non-assessable, and will be free of any taxes, liens, charges or encumbrances of any nature whatsoever; provided, that the
Preferred Stock issuable pursuant to this Agreement may be subject to restrictions on transfer under state and/or federal securities laws. The Company has made available to the Warrantholder true, correct and complete copies of its Charter and
bylaws currently in effect. The issuance of certificates for shares of Preferred Stock upon exercise of this Agreement shall be made without charge to the Warrantholder for any issuance tax in respect thereof, or other cost incurred by the Company
in connection with such exercise and the related issuance of shares of Preferred Stock; provided, that the Company shall not be required to pay any tax which may be payable in respect of any transfer and the issuance and delivery of any
certificate in a name other than that of the Warrantholder. 
 (b) Due Authority. The execution and delivery by the
Company of this Agreement and the performance of all obligations of the Company hereunder, including the issuance to Warrantholder of the right to acquire the shares of Preferred Stock and the Common Stock into which it may be converted, have been
duly authorized by all necessary corporate action on the part of the Company. This Agreement: (1) does not violate the Charter or current bylaws; (2)

  
 7 

 
does not contravene any law or governmental rule, regulation or order applicable to it; and (3) does not and will not contravene any provision of, or constitute a default under, any
indenture, mortgage, contract or other instrument to which it is a party or by which it is bound. This Agreement constitutes a legal, valid and binding agreement of the Company, enforceable in accordance with its terms except (a) as limited by
applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors’ rights generally, and (b) as limited by laws relating to the availability of specific performance,
injunctive relief, or other equitable remedies. 
 (c) Consents and Approvals. No consent or approval of, giving of
notice to, registration with, or taking of any other action in respect of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and performance by the Company of its obligations under this
Agreement, except for the filing of notices pursuant to Regulation D under the Act and any filing required by applicable state securities law, which filings will be effective by the time required thereby. 

(d) Issued Securities. All issued and outstanding shares of Common Stock, Series C-1 Preferred Stock or any other securities of
the Company have been duly authorized and validly issued and are fully paid and nonassessable. All outstanding shares of securities were issued in full compliance with all federal and state securities laws. In addition, as of January 4, 2011:

 (i) The authorized capital of the Company consists of (A) 25,150,000 shares of Common Stock, of which
6,086,081 shares are issued and outstanding, (B) 2,461,600 shares of Series A Preferred Stock, of which 2,461,600 shares are issued and outstanding and are convertible into 2,461,600 shares of Common Stock, (C) 6,458,000 shares of Series B
Preferred Stock, of which 6,450,000 shares are issued and outstanding and are convertible into 6,450,000 shares of Common Stock, (D) 3,520,000 shares of Series C Preferred Stock, of which 3,520,000 shares are issued and outstanding and are
convertible into 3,520,000 shares of Common Stock, and (E) 3,255,238 shares of Series C-1 Preferred Stock, of which 3,105,238 shares are issued and outstanding and are convertible into 3,105,238 shares of Common Stock. 

(ii) The Company has reserved 5,000,000 shares of Common Stock for issuance under its 2006 Stock Incentive Plan, under
which options to purchase an aggregate of 2,538,002 shares of Common Stock are outstanding. Other than under the 2006 Stock Incentive Plan, a warrant to purchase an aggregate of 8,000 shares of Series B Preferred Stock and the preferred stock
described in clause (i) above, there are no other options, warrants, conversion privileges or other rights presently outstanding to purchase or otherwise acquire any authorized but unissued shares of the Company’s capital stock or other
securities of the Company. 
 (iii) Except as set forth in the Rights Agreement, no stockholder of the Company
has preemptive rights to purchase new issuances of the Company’s capital stock. 
 (e) Other Commitments to Register
Securities. Except as set forth in this Agreement and the Rights Agreement, the Company is not, pursuant to the terms of any other agreement currently in existence, under any obligation to register under the Act any of its presently outstanding
securities or any of its securities which may hereafter be issued. 
 (f) Exempt Transaction. Subject to the accuracy of
the Warrantholder’s representations set forth in Section 10, the issuance of the Preferred Stock upon exercise of this Agreement, and the issuance of the Common Stock upon conversion of the Preferred Stock, will each constitute a
transaction exempt from (i) the registration requirements of Section 5 of the Act and (ii) the qualification requirements of the applicable state securities laws. 

  
 8 

 (g) Compliance with Rule 144. If the Warrantholder proposes to sell Preferred Stock
issuable upon the exercise of this Agreement, or the Common Stock into which it is convertible, in compliance with Rule 144 promulgated by the SEC, then, upon the Warrantholder’s written request to the Company, the Company shall furnish to the
Warrantholder, within ten (10) days after receipt of such request, a written statement indicating whether the Company is in compliance with the filing requirements of the SEC as set forth in such Rule, as such Rule may be amended from time to
time. 
 (h) Information Rights. During the term of this Warrant, the Company shall furnish to the Warrantholder the
reports that it furnishes to the Major Stockholders (as defined in the Rights Agreement) pursuant to Section 1.1 of the Rights Agreement. 
  

	 	SECTION 10.	REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER. 

 This Agreement has been entered into by the Company in reliance upon the following representations and covenants of the Warrantholder: 

(a) Investment Purpose. This Agreement and the Preferred Stock issuable upon exercise of the Warrantholder’s rights contained
herein are and will be acquired for investment and not with a view to the sale or distribution of any part thereof, and the Warrantholder has no present intention of selling or engaging in any public distribution of the same except pursuant to a
registration or exemption. 
 (b) Private Issue. The Warrantholder understands (i) that the Preferred Stock issuable
upon exercise of this Agreement is not registered under the Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Agreement will be exempt from the registration and qualifications requirements
thereof, and (ii) that the Company’s reliance on such exemption is predicated on the representations set forth in this Section 10. 
 (c) Financial Risk. The Warrantholder has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of its investment, and has the ability
to bear the economic risks of its investment. 
 (d) Risk of No Registration. The Warrantholder understands that if the
Company does not register with the SEC pursuant to Section 12 of the Securities Exchange Act of 1934 (the “1934 Act”), or file reports pursuant to Section 15(d) of the 1934 Act, or if a registration statement covering the
securities under the Act is not in effect when it desires to sell (i) the rights to purchase Preferred Stock pursuant to this Agreement or (ii) the Preferred Stock issuable upon exercise of the right to purchase, it may be required to hold
such securities for an indefinite period. The Warrantholder also understands that any sale of (A) its rights hereunder to purchase Preferred Stock or (B) Preferred Stock issued or issuable hereunder which might be made by it in reliance
upon Rule 144 under the Act may be made only in accordance with the terms and conditions of that Rule. 
 (e) Accredited
Investor. Warrantholder is an “accredited investor” within the meaning of the Securities and Exchange Rule 501 of Regulation D, as presently in effect. 
 (f) Market “Stand-off” Agreement. Warrantholder agrees, if requested by the Company, (a) not to (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell
any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, this Warrant, the Preferred Stock or other shares of capital
stock issuable upon exercise of this Warrant (or the conversion of 

  
 9 

 
any such shares), or any other securities of the Company or (ii) enter into any swap or other arrangement that transfers, in whole or in part, any of the economic consequences of ownership
of this Warrant, the Preferred Stock or other shares of capital stock issuable upon exercise of this Warrant (or the conversion of any such shares), or any other securities of the Company (excluding securities acquired in the Initial Public Offering
or in the public market after the Initial Public Offering), whether any transaction described in clause (i) or (ii) is to be settled by delivery of securities, in cash or otherwise, during the period beginning on the date of the filing of
the registration statement relating to the Initial Public Offering with the SEC and ending 180 days after the date of the final prospectus relating to the Initial Public Offering (plus up to an additional 34 days to the extent requested by the
managing underwriters for such offering in order to address Rule 2711(f) of the National Association of Securities Dealers, Inc. or any similar successor provision) and (b) to execute any agreement reflecting clause (a) above as may be
requested by the Company or the managing underwriters of the Initial Public Offering. In order to enforce the foregoing, the Company may impose stop-transfer instructions with respect to such securities until the end of such lock-up period and may
cause such securities to bear a legend setting forth such restriction until the end of such lock-up period. The underwriters for the Initial Public Offering are intended third party beneficiaries of this Section 10(f) and shall have the right,
power and authority to enforce the provisions hereof as though they were parties hereto. This Section 10(f) shall be effective only if all of the officers, directors, and holders of more than 5% of the Company’s Preferred Stock are bound
by the same provisions. 
  

	 	SECTION 11.	TRANSFERS. 

 Subject to
compliance with applicable federal and state securities laws, this Agreement and all rights hereunder are transferable, in whole and not in part, without charge to the holder hereof (except for transfer taxes) upon surrender of this Agreement
properly endorsed. Each taker and holder of this Agreement, by taking or holding the same, consents and agrees that this Agreement, when endorsed in blank, shall be deemed negotiable, and that the holder hereof, when this Agreement shall have been
so endorsed and its transfer recorded on the Company’s books, shall be treated by the Company and all other persons dealing with this Agreement as the absolute owner hereof for any purpose and as the person entitled to exercise the rights
represented by this Agreement. The transfer of this Agreement shall be recorded on the books of the Company upon receipt by the Company of a notice of transfer in the form attached hereto as Exhibit III (the “Transfer
Notice”) at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. Until the Company receives such Transfer Notice, the Company may treat the registered owner
hereof as the owner for all purposes. Notwithstanding the foregoing, this Agreement shall not be transferable to any competitor of the Company prior to the Initial Public Offering (as determined in good faith by the Board of Directors of the
Company). 
  

	 	SECTION 12.	MISCELLANEOUS. 

 (a) Effective
Date. The provisions of this Agreement shall be construed and shall be given effect in all respects as if it had been executed and delivered by the Company on the date hereof. This Agreement shall be binding upon any successors or assigns of the
Company and the Warrantholder. 
 (b) Remedies. In the event of any default hereunder, the non-defaulting party may
proceed to protect and enforce its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where the
non-defaulting party will not have an adequate remedy at law and where damages will not be readily ascertainable. Each party expressly agrees that it shall not oppose an application by the other party or any other person entitled to the benefit of
this Agreement requiring specific performance of any or all provisions hereof or enjoining a party from continuing to commit any such breach of this Agreement. 

  
 10 

 (c) Additional Documents. The Company, upon execution of this Agreement, shall
provide the Warrantholder with certified resolutions with respect to the representations, warranties and covenants set forth in Sections 9(a) through 9(d) and 9(f). 
 (d) Attorney’s Fees. In any litigation, arbitration or court proceeding between the Company and the Warrantholder relating hereto, the prevailing party shall be entitled to attorneys’
fees and expenses and all costs of proceedings incurred in enforcing this Agreement. For the purposes of this Section 12(d), attorneys’ fees shall include without limitation fees incurred in connection with the following: (i) contempt
proceedings; (ii) discovery; (iii) any motion, proceeding or other activity of any kind in connection with an insolvency proceeding; (iv) garnishment, levy, and debtor and third party examinations; and (v) post-judgment motions
and proceedings of any kind, including without limitation any activity taken to collect or enforce any judgment. 
 (e)
Severability. In the event any one or more of the provisions of this Agreement shall for any reason be held invalid, illegal or unenforceable, the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or
unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the parties underlying the invalid, illegal or unenforceable provision. 

(f) Notices. Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process
or other communication that is required, contemplated, or permitted under this Agreement or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the
earlier of: (i) the day of transmission by facsimile, electronic transmission or hand delivery if such transmission or delivery occurs on a business day at or before 5:00 pm in the time zone of the recipient, or, if transmission or delivery
occurs on a non-business day or after such time, the first business day thereafter, or the first business day after deposit with an overnight express service or overnight mail delivery service; or (ii) the third calendar day after deposit in
the United States mails, with proper first class postage prepaid, and shall be addressed to the party to be notified as follows: 
 If to Warrantholder: 
 Hercules Technology III, L.P. 

Legal Department 
 Attention: Chief Legal Officer and Manuel Henriquez 
 400 Hamilton
Avenue, Suite 310 
 Palo Alto, CA 94301 

Facsimile: 650-473-9194 
 Telephone: 650-289-3060 
 Email: pshah@herculestech.com 

If to the Company: 
 BIND BIOSCIENCES, INC. 
 64 Sidney Street 

Cambridge, MA 02139 
 Attention: Chief Financial Officer 
 Facsimile: 617-491-0351

 Telephone: 617-491-3400 

Email: afranz@bindbio.com 

  
 11 

 With a copy to: 

WilmerHale 
 60 State Street 
 Boston, MA 02109 

Attention: Peter Handrinos 
 Facsimile: 617-526-5000 
 Telephone: 617-526-6158 

Email: peter.handrinos@wilmerhale.com 
 or to such other address as each party may designate for itself by like notice, provided that any notice delivered to Warrantholder or Company shall be valid notwithstanding the failure to deliver a copy
of such notice to any other person or entity. 
 (g) Entire Agreement; Amendments. This Agreement constitute the entire
agreement and understanding of the parties hereto in respect of the subject matter hereof, and supersede and replace in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written or oral,
with respect to the subject matter hereof. None of the terms of this Agreement may be amended except by a written instrument executed by each of the parties hereto. 
 (h) Headings. The various headings in this Agreement are inserted for convenience only and shall not affect the meaning or interpretation of this Agreement or any provisions hereof. 

(i) No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the
event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the
authorship of any provisions of this Agreement. 
 (j) No Waiver. No omission or delay by Warrantholder at any time to
enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by the Company at any time designated, shall be a waiver of any such right or remedy to which Warrantholder is entitled, nor
shall it in any way affect the right of Warrantholder to enforce such provisions thereafter. 
 (k) Survival. All
agreements, representations and warranties contained in this Agreement or in any document delivered pursuant hereto shall be for the benefit of Warrantholder and shall survive the execution and delivery of this Agreement and the expiration or other
termination of this Agreement. 
 (l) Governing Law. This Agreement shall be governed by, and construed and enforced in
accordance with, the laws of the State of Delaware, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 
 (m) Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Agreement may be brought in any state or federal court of competent jurisdiction located in
Santa Clara County, State of California. By execution and delivery of this Agreement, each party hereto generally and unconditionally: (a) consents to personal jurisdiction in Santa Clara County, California; (b) waives any objection as to
jurisdiction or venue in Santa Clara County, California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in
connection with this Agreement. 

  
 12 

 (n) Mutual Waiver of Jury Trial. Because disputes arising in connection with complex
financial transactions are most quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved
by a judge applying such applicable laws. EACH OF THE COMPANY AND WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY,
“CLAIMS”) ASSERTED BY THE COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR BY THE WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY. This waiver extends to all such Claims, including Claims that involve Persons other than the Company and
Warrantholder; Claims that arise out of or are in any way connected to the relationship between the Company and Warrantholder; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind,
arising out of this Agreement. 
 (o) Counterparts. This Agreement and any amendments, waivers, consents or supplements
hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same
instrument. 
 (p) Specific Performance. The parties hereto hereby declare that it is impossible to measure in money the
damages which will accrue to Warrantholder or Company by reason of the other’s failure to perform any of the obligations under this Agreement and agree that the terms of this Agreement shall be specifically enforceable by Warrrantholder and
Company, as applicable. If Warrantholder or Company institutes any action or proceeding to specifically enforce the provisions hereof, any person against whom such action or proceeding is brought hereby waives the claim or defense therein that the
instituting entity has an adequate remedy at law, and such person shall not offer in any such action or proceeding the claim or defense that such remedy at law exists. 

  
 13 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by its officers thereunto
duly authorized as of the Effective Date. 
  

									
		 	COMPANY:	 		 	BIND BIOSCIENCES, INC.
					
		 		 		 	By:	 	 /s/ Andrea Franz

					
		 		 		 	Title:	 	 Chief Financial Officer

				
		 	WARRANTHOLDER:	 		 	HERCULES TECHNOLOGY III, L.P.,
		 		 		 	a Delaware limited partnership
		 		 		 	 By: Hercules Technology SBIC Management, LLC,
 its General Partner

		 		 		 	 By: Hercules Technology Growth Capital, Inc.,
 its Manager

					
		 		 		 	By:	 	 /s/ Ben Bang

					
		 		 		 	Title:	 	 Senior Counsel

 EXHIBIT I 
 NOTICE OF EXERCISE 
  

	To:	BIND Biosciences, Inc. 

  

	(1)	The undersigned Warrantholder hereby elects to purchase [            ] shares of the Series
[    ] Preferred Stock of [                            ], pursuant to the terms of the
Agreement dated the [    ] day of [        ,         ] (the “Agreement”) between
[                            ] and the Warrantholder, and [CASH PAYMENT: tenders herewith payment of the
Purchase Price in full, together with all applicable transfer taxes, if any.] [NET ISSUANCE: elects pursuant to Section 3(a) of the Agreement to effect a Net Issuance.] 

 

	(2)	Please issue a certificate or certificates representing said shares of Series [    ] Preferred Stock in the name of the undersigned or in such other
name as is specified below. 

  

							
		 		 	  

			
		 		 	(Name)
			
		 		 	  

		 		 	(Address)
		
	 WARRANTHOLDER:
	 	 HERCULES TECHNOLOGY III, L.P.,
 a Delaware limited partnership
 By: Hercules Technology SBIC Management, LLC,

its General Partner
 By: Hercules Technology
Growth Capital, Inc.,
 its Manager

				
		 		 	By:	 	  

				
		 		 	Title:	 	  

				
		 		 	Date:	 	  

 EXHIBIT II 
 ACKNOWLEDGMENT OF EXERCISE 
 The undersigned
[                                        ],
hereby acknowledge receipt of the “Notice of Exercise” from Hercules Technology III, L.P. to purchase [            ] shares of the Series [    ] Preferred
Stock of [                        ], pursuant to the terms of the Agreement, and further acknowledges that
[            ] shares remain subject to purchase under the terms of the Agreement. 
  

							
	 COMPANY:
	 		 	BIND BIOSCIENCES, INC.
				
		 		 	By:	 	  

				
		 		 	Title:	 	  

				
		 		 	Date:	 	  

  
 16 

 EXHIBIT III 
 TRANSFER NOTICE 
 (To transfer or assign the foregoing Agreement execute this form and supply
required information. Do not use this form to purchase shares.) 
 FOR VALUE RECEIVED, the foregoing Agreement and all rights evidenced thereby
are hereby transferred and assigned to 
  

					
	  
	 	
	(Please Print)	 	
			
	whose address is	 	  
	 	
		
	  
	 	

  

					
		  	Dated:	  	  

			
		  	Warrantholder’s Signature:	  	  

			
		  	Warrantholder’s Address:	  	  

			
		  		  	  

  
 17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}]]